The ILKAP Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human liver adenocarcinoma cell line SK-HEP-1, engineered to disrupt the ILKAP gene. This product provides a genetically defined loss-of-function model for investigating the tumor-suppressive roles of ILKAP phosphatase activity in hepatocellular carcinoma biology. The polyclonal format, generated by CRISPR/Cas9-mediated gene disruption, ensures a heterogeneous population of knockout cells, enabling robust assessment of ILKAP-dependent phenotypes without clonal selection biases. Researchers can utilize these cells to dissect ILKAP-mediated signaling networks and their impact on cancer cell behavior.
SK-HEP-1 is an extensively characterized human liver adenocarcinoma cell line derived from the ascitic fluid of a patient with liver adenocarcinoma. It is widely employed in hepatic cancer research, particularly for studies focusing on metastasis, epithelial-to-mesenchymal transition, and signal transduction. The cells exhibit adherent epithelial morphology and retain key malignant properties, making them a suitable host for generating ILKAP knockout models. The SK-HEP-1 background provides a physiologically relevant context for examining how loss of ILKAP function influences hepatocellular carcinoma progression and the underlying molecular mechanisms.
ILKAP encodes a serine/threonine phosphatase that specifically dephosphorylates integrin-linked kinase (ILK), a central component of the ILK-PINCH-parvin complex. By dephosphorylating ILK at critical residues, ILKAP inhibits ILK activity and suppresses downstream AKT/GSK3??/??-catenin signaling. This regulation is triggered by upstream factors such as Wnt ligands and growth factors that modulate ILKAP expression or activity. ILKAP directly interacts with ILK, and its activity leads to reduced phosphorylation of AKT, decreased inhibition of GSK3??, and enhanced ??-catenin degradation, thereby attenuating Wnt/??-catenin-driven transcription. Consequently, ILKAP functions as a negative regulator of cell proliferation and migration, primarily by restraining ILK-dependent signaling cascades.
In the SK-HEP-1 hepatocellular carcinoma cell line, ILKAP knockout is expected to enhance ILK activity and downstream signaling through AKT, GSK3??, and ??-catenin. This perturbation likely promotes cell adhesion alterations, increased migratory capacity, and activation of Wnt target genes, mirroring events that drive metastasis in liver cancer. The model enables detailed investigation of how ILKAP loss contributes to tumor progression in a liver-specific context, providing insights into integrin-mediated adhesion pathways and their crosstalk with Wnt signaling. By comparing polyclonal knockout populations to parental SK-HEP-1 cells, researchers can evaluate the impact of ILKAP disruption on cellular transformation and metastatic potential.
This product is designed for a wide range of applications in biomedical research. Users can employ western blotting to assess phospho-ILK levels and monitor changes in downstream effectors such as phospho-AKT, phospho-GSK3??, and ??-catenin. Cell migration and invasion assays, including transwell and scratch wound methods, facilitate the study of ILKAP-dependent motility. Co-immunoprecipitation experiments allow examination of ILK complex integrity (e.g., ILK-PINCH-parvin interactions) in the absence of ILKAP. Additionally, dual-luciferase reporter assays can measure Wnt/??-catenin transcriptional activity, directly linking ILKAP loss to pathway output. These cells are ideal for studying tumor suppression mechanisms, Wnt signaling regulation, and cancer cell migration in a hepatocellular carcinoma model. For further details, please contact Ascent Research.
